Joint Statement by Baillieu Limited Chairperson David Trude and Managing Director Gavin Powell

Read Statement

EL&C Baillieu successfully raises $15mn for 4DX in a heavily oversubscribed pre-IPO offering

As lead manager, EL&C Baillieu Director and Head of Corporate Finance Steve Macaw and his team have successfully raised $15 million in a heavily oversubscribed pre-IPO offering for leading Australian medical technology company 4DX.

4Dx is a software company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders, including, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4Dx technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing the subtlest variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

The funds raised via the unsecured converting note issue will be used to drive 4Dx’s go-to-market strategy by adding to the US sales and distribution capability and augmenting the Software-as-a-Service (Saas) sales platform, as well as continued product research and development.

“The scale of the demand is encouraging as we head toward an initial public offering,” said Chairman and CEO Andreas Fouras. “This shows the market is starting to recognise the significant opportunity presented by our unique four-dimensional lung imaging technology and our well-defined commercial strategy.”

Click here to read more

Back To Top